12 April 2016 - Merck today announced that the U.S. FDA has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite sublingual allergy immunotherapy (SLIT) tablet.

The BLA for Merck's investigational house dust mite SLIT-tablet is supported by a comprehensive clinical program involving more than 4,000 patients, including two Phase III in-field trials that evaluated the efficacy and safety of MK-8237 in house dust mite-induced allergic rhinitis with or without conjunctivitis.

Merck's house dust mite SLIT-tablet is an investigational sublingual immunotherapy dissolvable tablet designed to help treat allergic rhinitis with or without conjunctivitis caused by house dust mite-specific allergens. Merck has partnered with ALK-Abelló to develop its house dust mite SLIT-tablet in North America.

For more details, go to: http://www.mercknewsroom.com/news-release/merck-announces-fda-acceptance-biologics-license-application-investigational-house-dust